Emergent Biosolutions (EBS) Stock Statistics & Valuation Metrics

Emergent Biosolutions has a market cap or net worth of $343.58M. The enterprise value is $863.98M.

Emergent Biosolutions has 54,277,830 shares outstanding. The number of shares has decreased by -2.65% in one year.

Emergent Biosolutions’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -11.81%.

The current PE Ratio of Emergent Biosolutions is -2.66. Emergent Biosolutions’s PEG ratio is -0.09.

In the last 12 months, Emergent Biosolutions had revenue of 1.01B and earned -190.60M in profits. Earnings per share was -3.60.

In the last 12 months, operating cash flow was 110.10M and capital expenditures -15.70M, giving a free cash flow of 94.40M billion.

Emergent Biosolutions pays an annual dividend of $1.855, resulting in a dividend yield of ―

Emergent Biosolutions upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.

Emergent Biosolutions as a current ratio of 3.69, with Debt / Equity ratio of 120.45%

In the past 12 months, Emergent Biosolutions has paid 47.70M in taxes.

Emergent Biosolutions EV to EBITDA ratio is 29.02, with an EV/FCF ratio of 29.91.

Emergent Biosolutions has $149.10M in cash and marketable securities with $665.70M in debt, giving a net cash position of $516.60M billion.

Gross margin is 31.60%, with operating margin of -10.72%, and net profit margin of -18.80%.

The average price target for Emergent Biosolutions is $13.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy